Header image  
www.adipobiotech.com  
  

 
 
 
 
 
 

基质金属蛋白酶-9 酶联试剂

  • 总基质金属蛋白酶-9是一个心血管疾病早期预警的监测信号。
  • Plasma MMP-9 after AMI correlated with circulating WBC and neutrophil count;
  • Higher plasma MMP-9 was associated with more severe LVSD in the immediate post-AMI period;
  • Higher MMP-9 levels during index hospitalization predict greater LV remodelling in the weeks after AMI;
  • Following the fall from the early peak level, higher plateau levels of MMP-9 are associated with relative preservation of LV function and less extensive remodelling.
Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J. 2007 March; 28(6): 711–718.
总基质金属蛋白酶-9(人)酶联免疫试剂盒
产品号 SK00160-01
标准曲线范围: 0.312 ~ 20 ng/ml
检测灵敏度 0.156 ng/ml
样本体积 100 ul
样本稀释 血清、唾液、尿液和细胞培养液100倍
  血浆是40倍稀释
批内误差 2.9%
批间误差 7.9%
交叉反应 human MMP-9 100%
样本检测 血清:169 - 705 ng/ml
样本检测 血浆:13.2 - 105 ng/ml


____________________________________________________

总基质金属蛋白酶-9(人)酶联免疫试剂盒

产品目录号:SK00160-02

ELISA Protocol

总基质金属蛋白酶-9(人)酶联免疫试剂盒
产品目录号 SK00160-02
标准曲线范围: 0.030 ~ 2 ng/ml
检测灵敏度 20 pg/ml
样本体积 100 ul
样本稀释 血清、唾液、尿液和细胞培养液500倍
  血浆是100倍稀释
批内误差 4.9%
批间误差 5.9%
交叉反应 human MMP-9 100%
样本检测 血清:169 - 705 ng/ml
样本检测 血浆:13.2 - 105 ng/ml

—————————————————————————————————

 

总基质金属蛋白酶-9(小鼠)酶联免疫试剂盒
标准曲线范围: 0.078 ~5 ng/ml
检测灵敏度:0.007 ng/ml
样本体积:50微升
样本稀释:血清需要50倍;血浆需要40倍 (加入稀释后的样本浓度仍高于25ng/ml, 可能还要继续稀释一定的倍数)
批内误差:5.1~8.4%
批间误差:7.8~9.6%
交叉反应:小鼠的MMP-9是100%;与人或大鼠的不交叉
样本检测:血清 (n=20)121 +- 44 ng/ml
样本检测:血浆 (EDTA, n=20) 59 +- 48 ng/ml

 

_________________________________________________________

MMP-9/NGAL复合体(人)酶联免疫试剂盒
标准曲线范围: 0.312 ~ 20 ng/ml
检测灵敏度 0.013 ng/ml
样本体积 100 ul
样本稀释 血清、唾液、尿液和细胞培养液100倍
  血浆是40倍稀释
批内误差 4.1%
批间误差 7.6%
交叉反应 与人MMP-9或NGAL无交叉反应
样本检测 血清:8.7 - 164 ng/ml
样本检测 血浆:1.92 - 44.8 ng/ml
样本检测 唾液:7.38 - 109 ng/ml

 

NGAL, also known as lipocalin-2, is a member of the lipocalin family that is comprised of functionally diverse but structurally conserved small proteins . NGAL has been implicated in a variety of processes including inflammation, apoptosis, and organogenesis, and is a promising biomarker for acute renal failure . NGAL biosynthesis is stimulated by the Toll-like receptors on immune cells upon bacterial invasion; secreted NGAL then limits bacterial growth by sequestrating the iron-laden siderophore. NGAL exists as monomer (25 kDa), homodimer, and disulfide bond-linked heterodimer with MMP-9. The MMP-9/NGAL complex (125 kDa) is one of several MMP forms with high molecular weights (> 100 kDa) detected in the urine of cancer patients . NGAL is proposed to modulate MMP-9 activity by protecting it from degradation.

 

 

 

电子信箱 Info@AdipoBiotech.com
电话号码 010-81786624; 81786244


试剂盒名称 目录号
规格
价格(元)
总基质金属蛋白酶-9(人)酶联免疫试剂盒 SK00160-01
96T
5950
总基质金属蛋白酶-9(人)酶联免疫试剂盒 SK00160-02
96T
4200
总基质金属蛋白酶-9(人)酶联免疫试剂盒 SK00160-02B
192T
7000
MMP-9/NGAL复合体(人)酶联免疫试剂盒 SK00160-04
96T
6400
总基质金属蛋白酶-9(小鼠)酶联免疫试剂盒 SK00160-03
96T
5920
总基质金属蛋白酶-9(人) 样本酶联免疫检测 S00160-02
80个起
50
总基质金属蛋白酶-9(人) 样本酶联免疫检测 S00160-01
80个起
75
MMP-9/NGAL复合体(人)样本酶联免疫检测 S00160-02
80个起
87
总基质金属蛋白酶-9(小鼠)样本酶联免疫检测 S00160-03
80个起
75

 

Temporal profiles of MMP-2 (upper) and MMP-9 (lower) post-AMI. Data are median with upper and lower quartiles and range. Asterisk indicates P < 0.05 anterior vs. inferior territory of AMI.
Upper panel: LVEF according to peak MMP-9 below or above the median value (113 ng/mL). Lower panel: LVEF according to plateau MMP-9 below or above the median value (36.4 ng/mL).